Institut für Prävention und Gesundheitsförderung an der Universität Duisburg-Essen, Max-Fiedler Strasse 6, 45128 Essen, Germany.
Eur J Health Econ. 2010 Oct;11(5):449-55. doi: 10.1007/s10198-009-0181-2. Epub 2009 Sep 23.
Patients with acute coronary syndrome (ACS) are in need of cost-intensive treatment involving different aspects of the German Health System. Percutaneous coronary intervention (PCI) is the treatment of choice for a large proportion of cases. In the present study, an analysis of the cost impact of ACS with focus on PCI therapy was conducted across-the-board for the German Health System. Results indicated that 85% of all costs arising from treatment of ACS with a trial of PCI are due to in-patient care. Projection of results onto the entire insurant collective of the statutory health system estimated a total of Euro 954,995,603-a proportional 0.7% of all expenditure by statutory health insurance in 2005.
患有急性冠状动脉综合征(ACS)的患者需要进行涉及德国卫生系统多个方面的高成本治疗。经皮冠状动脉介入治疗(PCI)是很大一部分病例的首选治疗方法。在本研究中,对德国卫生系统中广泛关注的 ACS 的成本影响进行了分析。结果表明,在 PCI 治疗的 ACS 治疗中,85%的所有费用都归因于住院治疗。将结果预测到法定健康保险的整个被保险人集体中,估计总额为 954,995,603 欧元——这是 2005 年法定健康保险支出的 0.7%。